Project Grant R01AR084498
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$313K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Regents of the University of Colorado (CU) for the project "GRANULAR HYDROGELS FOR THE CONTROLLED DELIVERY OF IMMUNOMODULATORY AND ANGIOGENIC EXTRACELLULAR VESICLES TO ENHANCE BONE TISSUE REGENERATION". The grant, awarded on July 4, 2024, supports CU's research to develop novel...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to establish a new "microphysiological joint-on-chip" system for the study of arthritic diseases and rapid testing of treatment candidates. The $618,629 award, effective from August 15, 2024 to July 31, 2029, will fund the development of human-derived biomaterial inks and...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), totaling $599,693, supports research focused on elucidating molecular pathways and mechanisms that regulate myeloid cell function and osteoclastogenesis under pathological inflammatory conditions, with the goal of developing new therapeutic approaches to suppress pathological bone...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $393,412 Project Grant under CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research) to Vanderbilt University. The grant, which runs from September 17, 2024 to July 31, 2029, supports research to develop engineered cell therapies as agents for arthritis treatment. Key objectives include characterizing synthetic receptors to drive cartilage repair in an in vitro arthropathy model (Aim 1),...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,700 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, Irvine (UC Irvine) to develop a novel therapeutic approach for improving angiogenesis and wound healing. The project aims to deliver apoptotic neutrophils within a degradable hydrogel scaffold to stimulate macrophages and promote their angiogenic signaling and tissue repair without...
This $375,100 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to identify myeloid progenitors that maintain cortical bone with aging and characterize cells/molecules that promote coupling within cortical bone. The goal is to spur the development of new therapeutics to limit age-associated cortical bone loss. The award was made to the...
This $571,650 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research program) supports research to repurpose FDA-approved drugs for the treatment of osteoarthritis. The project aims to use high-throughput screening in innovative human cell-derived microphysiological models to identify and evaluate potential disease-modifying osteoarthritis drugs (DMOADs). Key aspects...
This $313,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research by Emory University to establish phosphorylated WNT5A produced by osteoclasts as a potential anabolic bone drug. The research aims to determine how osteoclast-derived phospho-WNT5A can enhance bone formation in vivo and elucidate the cellular and molecular mechanisms by...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $589,255 Project Grant (R01AR083421) to The Washington University to develop and test new nanoparticle-based strategies to treat heterotopic ossification (HO), a debilitating condition involving abnormal bone formation in soft tissues. The research aims to advance understanding of the mechanisms driving HO and identify new potential therapeutic targets. The project, funded through the Arthritis,...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $241,778 to Polymerix Technologies LLC to develop an improved process for manufacturing crosslinked ultra-high molecular weight polyethylene (UHMWPE) components for joint replacement implants. The key objectives are to optimize a pressure-quenching process to enhance the mechanical...